Gene
RPL21P80
| Entrez Gene ID | 100133273 (See on NCBI) |
| Description | ribosomal protein L21 pseudogene 80 |
| Gene Synonyms | RPL21_32_892 |
| Node consisting of this Gene | RPL21P80///RPL21P87///RPL21P37///RPL21P18///RPL21P16///RPL21P14///RPL21P134///RPL21P45///RPL21P119///RPL21P93///RPL21P98///RPL21P82///RPL21P46///RPL21P61///RPL21P69///RPL21P19///RPL21P62///RPL21P29///RPL21P44///RPL21P39///RPL21P97///RPL21 RPL21P80///RPL21P16///RPL21P119///RPL21P93///RPL21P39///RPL21P97///RPL21 |
Networks including this gene
| GSE10320_top8000 - GSE10320 - SiGN-BN NNSR | Predicting Relapse in Favorable Histology Wilms Tumor Using Gene Expression |
| GSE10797_top8000 - GSE10797 - SiGN-BN NNSR | Transcriptomes of breast epithelium and stroma in normal reduction mammoplasty and invasive breast cancer patients. |
| GSE11121_top8000 - GSE11121 - SiGN-BN NNSR | The humoral immune system has a key prognostic impact in node-negative breast cancer |
| GSE11869_top8000 - GSE11869 - SiGN-BN NNSR | The genomic response of a human uterine endometrial adenocarcinoma cell line to 17alpha-ethynyl estradiol. |
| GSE12093_top8000 - GSE12093 - SiGN-BN NNSR | The 76-gene Signature Defines High-Risk Patients that Benefit from Adjuvant Tamoxifen Therapy |
| GSE12682_top8000 - GSE12682 - SiGN-BN NNSR | Expression data from Human Kidney (HK) samples |
| GSE13009_top8000 - GSE13009 - SiGN-BN NNSR | MCF7 EGF, HRG stimulation |
| GSE13168_top8000 - GSE13168 - SiGN-BN NNSR | Effects of glucocorticoids and Protein Kinase A on growth factor- and 1beta- regulated gene |
| GSE13996_top8000 - GSE13996 - SiGN-BN NNSR | Molecular profiling of classical Hodgkin’s lymphoma tissues |
| GSE14764_top8000 - GSE14764 - SiGN-BN NNSR | A Prognostic Gene Expression Index in Ovarian Cancer |
| GSE14925_top8000 - GSE14925 - SiGN-BN NNSR | Expression data from Non small cell lung cancer cell lines |
| GSE15396_top8000 - GSE15396 - SiGN-BN NNSR | Peripheral blood mononuclear, DU145, and HCT116 cells treated with a CDK inhibitor |
| GSE15471_top8000 - GSE15471 - SiGN-BN NNSR | Whole-Tissue Gene Expression Study of Pancreatic Ductal Adenocarcinoma |
| GSE16515_top8000 - GSE16515 - SiGN-BN NNSR | Expression data from Mayo Clinic Pancreatic Tumor and Normal samples |
| GSE17705_top8000 - GSE17705 - SiGN-BN NNSR | Endocrine Sensitivity Index Validation Dataset |
| GSE17920_top8000 - GSE17920 - SiGN-BN NNSR | Expression data of diagnostic biopsy samples from Hodgkin lymphoma patients |
| GSE18521_top8000 - GSE18521 - SiGN-BN NNSR | A gene signature predictive for outcome in advanced ovarian cancer identifies a novel survival factor: MAGP2 |
| GSE19027_top8000 - GSE19027 - SiGN-BN NNSR | Antioxidant response gene expression in the bronchial airway epithelial cells of smokers at risk for lung cancer |
| GSE19069_top8000 - GSE19069 - SiGN-BN NNSR | Molecular signatures in peripheral T-cell lymphoma (PTCL) |
| GSE20181_top8000 - GSE20181 - SiGN-BN NNSR | Letrozole (Femara) early and late responses to treatment |
| GSE20194_top8000 - GSE20194 - SiGN-BN NNSR | MAQC-II Project: human breast cancer (BR) data set |
| GSE2034_top8000 - GSE2034 - SiGN-BN NNSR | Breast cancer relapse free survival |
| GSE2113_top8000 - GSE2113 - SiGN-BN NNSR | Plasma cell dyscrasias expression profiles associated with distinct IGH translocations in multiple myeloma |
| GSE21452_top8000 - GSE21452 - SiGN-BN NNSR | Integrated genomic profiling in mantle cell lymphoma |
| GSE22093_top8000 - GSE22093 - SiGN-BN NNSR | Expression data from breast cancer FNA biopsies from patients |
| GSE22597_top8000 - GSE22597 - SiGN-BN NNSR | Expression data from Fine Needle Aspiration (FNA) biopsies from breast cancer patients |
| GSE23120_top8000 - GSE23120 - SiGN-BN NNSR | Basal gene expression data from Human Variation Panel |
| GSE23878_top8000 - GSE23878 - SiGN-BN NNSR | Genome Wide Expression Analysis of Middle Eastern Colorectal Cancer Reveals FOXM1 as a Novel Target for Cancer Therapy |
| GSE23988_top8000 - GSE23988 - SiGN-BN NNSR | Expression data from breast cancer FNA biopsies from patients (US samples) |
| GSE25055_top8000 - GSE25055 - SiGN-BN NNSR | Discovery cohort for genomic predictor of response and survival following neoadjuvant taxane-anthracycline chemotherapy in breast cancer |
| GSE25065_top8000 - GSE25065 - SiGN-BN NNSR | Validation cohort for genomic predictor of response and survival following neoadjuvant taxane-anthracycline chemotherapy in breast cancer |
| GSE25066_top8000 - GSE25066 - SiGN-BN NNSR | Genomic predictor of response and survival following neoadjuvant taxane-anthracycline chemotherapy in breast cancer |
| GSE25136_top8000 - GSE25136 - SiGN-BN NNSR | Optimizing molecular signatures for prostate cancer recurrence |
| GSE2549_top8000 - GSE2549 - SiGN-BN NNSR | Malignant pleural mesothelioma |
| GSE2603_top8000 - GSE2603 - SiGN-BN NNSR | Subpopulations of MDA-MB-231 and Primary Breast Cancers |
| GSE27155_top8000 - GSE27155 - SiGN-BN NNSR | Human thyroid adenomas, carcinomas, and normals |
| GSE2841_top8000 - GSE2841 - SiGN-BN NNSR | Expression Profiling of pheochromocytomas of various genetic origins |
| GSE28497_top8000 - GSE28497 - SiGN-BN NNSR | New markers for minimal residual disease detection in acute lymphoblastic leukemia |
| GSE29013_top8000 - GSE29013 - SiGN-BN NNSR | Robust Gene Expression Signature from Formalin-Fixed Paraffin-Embedded Samples Predicts Prognosis of Non-Small-Cell Lung Cancer Patients |
| GSE29598_top8000 - GSE29598 - SiGN-BN NNSR | A Methodology for Utilization of Predictive Genomic Signatures in FFPE Samples |
| GSE30375_top8000 - GSE30375 - SiGN-BN NNSR | Gene expression data from sorted and unsorted primary human acute myeloid leukemia (AML) samples |
| GSE31245_top8000 - GSE31245 - SiGN-BN NNSR | Unique gene expression profile based upon pathologic response in epithelial ovarian cancer |
| GSE3141_top8000 - GSE3141 - SiGN-BN NNSR | Lung Cancer Dataset |
| GSE3143_top8000 - GSE3143 - SiGN-BN NNSR | Breast Cancer Dataset |
| GSE3149_top8000 - GSE3149 - SiGN-BN NNSR | Ovarian Cancer Dataset |
| GSE3151_top8000 - GSE3151 - SiGN-BN NNSR | Oncogene Signature Dataset |
| GSE31519_top8000 - GSE31519 - SiGN-BN NNSR | A Clinically Relevant Gene Signature in Triple-Negative and Basal-Like Breast Cancer |
| GSE3167_top8000 - GSE3167 - SiGN-BN NNSR | Classification of carcinoma in situ lesions in human bladder cancer |
| GSE32269_top8000 - GSE32269 - SiGN-BN NNSR | Expression data for primary localized prostate cancer versus castration-resistant bone metastatic prostate cancer |
| GSE3726_top8000 - GSE3726 - SiGN-BN NNSR | Prognostic gene signatures can be measured with samples stored in RNAlater |
| GSE4115_top8000 - GSE4115 - SiGN-BN NNSR | Airway Epithelial Gene Expression Diagnostic for the Evaluation of Smokers with Suspect Lung Cancer |
| GSE4573_top8000 - GSE4573 - SiGN-BN NNSR | Gene expression signatures for predicting prognosis of squamous cell lung carcinomas |
| GSE5327_top8000 - GSE5327 - SiGN-BN NNSR | Breast cancer relapse free survival and lung metastasis free survival |
| GSE5364_top8000 - GSE5364 - SiGN-BN NNSR | A Precisely Regulated Gene Expression Cassette Potently Modulates Metastasis and Survival in Multiple Solid Cancers |
| GSE5462_top8000 - GSE5462 - SiGN-BN NNSR | Letrozole (Femara) early response to treatment |
| GSE6462_top8000 - GSE6462 - SiGN-BN NNSR | MCF7 dose response |
| GSE6477_top8000 - GSE6477 - SiGN-BN NNSR | Expression data from different stages of plasma cell neoplasm |
| GSE6481_top8000 - GSE6481 - SiGN-BN NNSR | Gene Expression Analysis of Soft Tissue Sarcomas: Characterization & Reclassification of Malignant Fibrous Histiocytoma |
| GSE6691_top8000 - GSE6691 - SiGN-BN NNSR | Gene expression profiling of B lymphocytes and plasma cells from WaldenstrÖm’s macroglobulinemia. |
| GSE6956_top8000 - GSE6956 - SiGN-BN NNSR | Tumor Immunobiological Differences in Prostate Cancer between African-American and European-American Men |
| GSE7390_top8000 - GSE7390 - SiGN-BN NNSR | Strong Time Dependence of the 76-Gene Prognostic Signature |
| GSE7670_top8000 - GSE7670 - SiGN-BN NNSR | Expression data from Lung cancer |
| GSE7849_top8000 - GSE7849 - SiGN-BN NNSR | Age-Specific Differences of Oncogenic Pathway Deregulation Seen in Human Breast Tumors |
| GSE7904_top8000 - GSE7904 - SiGN-BN NNSR | Expression data from human breast tissue |
| GSE8057_top8000 - GSE8057 - SiGN-BN NNSR | Expression data from ovarian cancer cells with time-course and concentration-profiles |
| GSE8401_top8000 - GSE8401 - SiGN-BN NNSR | Gene Signature for Aggression of Melanoma Metastases - Melanoma Metastasis |
| GSE8481_top8000 - GSE8481 - SiGN-BN NNSR | Various human cell types |
| GSE8835_top8000 - GSE8835 - SiGN-BN NNSR | Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells. |
| GSE9348_top8000 - GSE9348 - SiGN-BN NNSR | Expression data from healthy controls and early stage CRC patient's tumor |
| GSE9750_top8000 - GSE9750 - SiGN-BN NNSR | Identification of gene expression profiles in cervical cancer |
| GSE9936_top8000 - GSE9936 - SiGN-BN NNSR | Expression data from human breast cancer cells (MCF-7) coexpressing ERalpha and Erbeta, treated with phytoestrogens |
(71 networks)
